The global research antibodies market is projected to reach USD 12.60 billion by 2022, at a CAGR of 6.2%.

The global research antibodies market (including reagents) is projected to reach USD 12.60 billion by 2022 from USD 9.33 billion in 2017, at a CAGR of 6.2%. This market is consolidated in nature with the presence of many local, regional, and global players. Thermo Fisher Scientific, Inc. (U.S.), Merck Group (Germany), Abcam plc (U.K.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and Cell Signaling Technology, Inc. (U.S.) were the major players in this market. These companies are mainly focusing on product launches, agreements, and acquisitions to strengthen their product offerings and establish a strong geographical foothold. 

Browse 187 Market Data Tables and 42 Figures spread through 279 Pages and in-depth TOC on "Research Antibodies Market".

http://www.marketsandmarkets.com/Market-Reports/research-antibodies-reagents-market-94212793.html

 Abcam plc dominated the global research antibodies market in 2016. Abcam focuses on product launches as its major growth strategy. Since 2013, the company has launched an exclusive range of research antibodies—Alexa Fluor 680/790 secondary antibodies, anti-PD-L1 primary antibodies, and Alexa Fluor 405/568/750 conjugated secondary antibodies. The company also focuses on inorganic growth strategies such as acquisitions to strengthen its position in the market. Abcam invests in the discovery of new antibody manufacturing technologies to speed up the pace of scientific research to increase their product offerings. The company’s strategic priority is to generate growth in the core reagents business by attracting new customers and establish new growth platforms.

Cell Signaling Technology, Inc. is growing at a rapid pace in this market by adopting various organic and inorganic growth strategies. In line with this, the company launched over six different types of monoclonal antibodies for tumor research in November 2015. Furthermore, between 2013 and 2015, the company has launched various primary antibodies, mainly for cancer research. CST also focuses on expanding its business globally to strengthen its position in the research antibodies market.

Thermo Fisher Scientific, Inc. is one of the leading players in the global research antibodies market in 2016. The company significantly focuses on product launches and product innovation. It also focuses on strengthening customer engagement through the provision of custom-made antibodies. Complementary acquisitions achieve the company's strategy to augment internal growth. In November 2016, the company acquired MTI-GlobalStem (U.S.), a stem cell research products firm. The increasing demand for high-quality research products, the growing proteomics and genomics research sector, and strong presence in the emerging markets are significant growth opportunities for the company to enhance its position in the research antibodies and reagents market.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownload.asp?id=94212793

The Merck Group commanded a significant share of the global research antibodies market in 2016. The company primarily focuses on product launches and expansions to expand its product offerings and increase its geographic coverage. Since 2013, the company has launched various antibodies and reagents in the research field. In January 2017, the company expanded its end-to-end biodevelopment centers in North America, China, and Europe. Merck also focuses on acquisitions & agreements as its key growth strategies. In November 2015, the company acquired Sigma-Aldrich, a leading life science company for USD 17 billion.

Becton, Dickinson and Company is another prominent player in the global research antibodies market. The company’s strong heritage of technology leadership and innovation has provided a solid foundation for the continued development of safe and cost-effective products and services. The company is concentrating on developing new products and expanding its customer reach. BD also focuses on the inorganic growth strategy of acquisitions to strengthen its product portfolio as well as its position in the market. In April 2017, it acquired C. R. Bard, Inc. (U.S.) for USD 24 billion. By acquiring CareFusion Corporation (U.S.) in March 2015, the company positioned itself as a leading player in the healthcare and life science market.